NCT03714737 is a Phase 3 clinical trial of experimental vaccine in Vaccine, sponsored by Jiangsu Province Centers for Disease Control and Prevention.

Who is sponsoring NCT03714737?

NCT03714737 is sponsored by Jiangsu Province Centers for Disease Control and Prevention.

What drugs are being tested in NCT03714737?

Interventions in NCT03714737: experimental vaccine, Positive control vaccine 1, Positive control vaccine 2.

Is NCT03714737 still recruiting?

NCT03714737 is currently completed. Last updated 22 October 2018.

Last reviewed 2018-10-22 · How we verify

NCT03714737

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

Completed Phase 3 Last updated 22 October 2018

What this trial tests

Phase 3 trial testing experimental vaccine in Vaccine in 1,950 participants. Completed in 6 September 2018.

Timeline

12 May 2016

Primary endpoint
11 September 2017

6 September 2018

Quick facts

Lead sponsor	Jiangsu Province Centers for Disease Control and Prevention
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	1,950
Start date	12 May 2016
Primary completion	11 September 2017
Estimated completion	6 September 2018

Drugs / interventions tested

experimental vaccine — full drug profile →
Positive control vaccine 1 — full drug profile →
Positive control vaccine 2 — full drug profile →

Conditions studied

Vaccine — all drugs for Vaccine →

Sponsor

Jiangsu Province Centers for Disease Control and Prevention — full company profile →

Who can join

Adults 3 Months to 5, any sex, with Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Invasive meningococcal disease and meningococcal meningitis caused by Neisseria meningitidis have their highest incidence in children, with a second peak in adolescents and young adults. The most important disease-causing serogroups are meningococcal serogroups A (MenA) and MenC in Asia, such as China. The specific vaccine use in each country depends on the predominant serogroups, cost, and availability. conjugate vaccines are preferred to polysaccharide vaccines due to their impact on decreasing nasopharyngeal carriage of N. meningitidis and their overall increased immunogenicity in children. This clinical trial is planning to evaluate the immunogenicity and safety of bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine in Chinese healthy children aged 3 months to 5 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China.
Hu J, Li H, Chu K, Liang Q, et al · · 2019 · cited 1× · PMID 31348731 · DOI 10.1080/21645515.2019.1627816

Verify or expand the search:

Other recruiting trials for Vaccine

Currently open trials in the same condition.

NCT07016152 — An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae · Phase 1 · recruiting
NCT06682117 — A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor · NA · recruiting
NCT06128928 — Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities · NA · recruiting
NCT04083950 — Induction of Gut Permeability by an Oral Vaccine · EARLY_PHASE1 · active not recruiting

Other Jiangsu Province Centers for Disease Control and Prevention trials

Trials by the same sponsor.

NCT07530679 — Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vacc · NA · not yet recruiting
NCT07232745 — Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine · Phase 4 · active not recruiting
NCT06609811 — The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuat · Phase 4 · completed
NCT07035054 — Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · Phase 2 · completed
NCT07025876 — PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03714737 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Province Centers for Disease Control and Prevention
Last refreshed: 22 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03714737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing